Remote Review of Chromatographic Data Under GMP

Remote Review of Chromatographic Data

Shahzaib Aftab

Learn GMP requirements for remote review of chromatographic data, including audit trails, ALCOA+, CDS validation, data integrity, and FDA compliance.

Table of Contents

Definition

Remote review of chromatographic data under GMP requirements involves evaluating electronic raw data, audit trails, metadata, system suitability results, integration events, and calculations through a validated Chromatography Data System (CDS). The process ensures compliance with ALCOA+ data integrity principles, FDA guidance, WHO expectations, and GMP requirements while enabling secure remote oversight of HPLC and GC analytical results.

Modern pharmaceutical laboratories increasingly rely on remote access technologies to support quality oversight, batch release decisions, internal audits, and global quality operations. While remote review offers flexibility and operational efficiency, it also introduces significant regulatory responsibilities.

Regulatory authorities such as the FDA, EMA, MHRA, WHO, and PIC/S expect pharmaceutical companies to maintain the same level of control over remotely reviewed chromatographic data as they would during on-site review.

Whether reviewing HPLC, UHPLC, GC, GC-MS, LC-MS, or dissolution chromatography data, reviewers must verify data integrity, traceability, and scientific validity directly within validated electronic systems.

This article explains GMP expectations, data integrity requirements, and practical best practices for conducting compliant remote chromatographic reviews.

Why Remote Chromatographic Data Review Matters

Chromatographic results support critical GMP decisions including:

  • Batch release
  • Stability testing
  • Method validation
  • OOS investigations
  • Cleaning validation
  • Impurity profiling
  • Regulatory submissions

Any weakness in data review may result in:

  • FDA Form 483 observations
  • Warning letters
  • Product recalls
  • Import alerts
  • Data integrity investigations

Regulatory Foundations for Remote Review

Several global regulations govern chromatographic data review.

Regulation / GuidanceRelevance
FDA Data Integrity GuidanceElectronic records and audit trails
21 CFR Part 11Electronic signatures and records
EU GMP Annex 11Computerized systems
EU GMP Chapter 4Documentation requirements
WHO TRS 1025Raw data and metadata expectations
PIC/S PI 041Data integrity guidance
ALCOA+ PrinciplesData governance framework

Understanding ALCOA+ in Remote Reviews

Every chromatographic review should verify compliance with ALCOA+ principles.

PrincipleReviewer Verification
AttributableAnalyst identity recorded
LegibleData readable and traceable
ContemporaneousData recorded when generated
OriginalRaw data preserved
AccurateCalculations and integrations verified
CompleteNo omitted injections
ConsistentSequence chronology maintained
EnduringData securely retained
AvailableAccessible throughout retention period

Remote reviewers should evaluate each principle before approving analytical results.

Key Elements of Remote Chromatographic Data Review

1. Audit Trail Review

Audit trail review is one of the most critical GMP expectations.

Reviewers must verify:

  • Method modifications
  • Integration changes
  • Sample weight edits
  • Sequence modifications
  • Processing method revisions
  • Result recalculations

Audit Trail Review Checklist

ItemReview Requirement
Method ChangesJustified and approved
Integration EventsScientifically justified
Deleted ResultsInvestigated
Reprocessing ActivitiesDocumented
Electronic SignaturesPresent and valid
Audit Trail LogsComplete

Regulatory Concern

Inspectors frequently cite laboratories that review chromatograms but fail to review associated audit trails.

2. Review Raw Data, Not Just Reports

A common GMP deficiency involves reviewing only:

  • Printed reports
  • PDF summaries
  • Exported spreadsheets

Instead, reviewers must access the original electronic record within the validated CDS.

Why Raw Data Review Is Essential

Reports may not reveal:

  • Deleted injections
  • Reprocessed chromatograms
  • Integration modifications
  • Audit trail events
  • Metadata changes

Regulators expect direct review of the original record.

3. Verify System Suitability Testing (SST)

Before sample data can be considered valid, SST requirements must be met.

Typical SST Parameters

ParameterPurpose
ResolutionPeak separation
Tailing FactorPeak symmetry
Theoretical PlatesColumn efficiency
%RSDPrecision
Retention TimeMethod consistency

Reviewer Responsibilities

Confirm:

✓ SST passed before sample injections

✓ Acceptance criteria documented

✓ No unauthorized reinjections

✓ Sequence order maintained

4. Assess Peak Integration

Peak integration directly impacts reported results.

Improper integration remains a common source of regulatory observations.

Review Considerations

Manual Integrations

Verify:

  • Scientific justification
  • SOP compliance
  • Approval documentation

Automated Integrations

Confirm:

  • Appropriate baseline assignment
  • Correct peak detection
  • No artificial peak manipulation

Red Flags

ObservationPotential Concern
Excessive manual integrationData manipulation
Baseline skimmingResult inflation
Peak truncationReporting bias
Selective reprocessingTesting into compliance

5. Verify Sequence Completeness

A complete chromatographic sequence review is essential.

Reviewers should inspect:

  • Blank injections
  • SST injections
  • Standards
  • Samples
  • Bracketing standards
  • Repeat injections

Sequence Integrity Checklist

Review AreaVerify
Missing InjectionsNone omitted
ReinjectionsJustified
Sequence OrderMaintained
Failed ResultsInvestigated
StandardsIncluded

6. Review Calculations and Reporting Methods

The CDS reporting method must accurately perform calculations.

Verify

  • Response factors
  • Potency corrections
  • Assay calculations
  • Purity calculations
  • Relative response factors
  • Impurity calculations

Common Findings

ObservationRegulatory Risk
Incorrect formulasInvalid results
Unauthorized editsData integrity concern
Missing calculationsCompliance issue

7. Confirm Reference Standard Compliance

Reference standards directly affect analytical accuracy.

Review Requirements

Verify standards are:

  • Qualified
  • Traceable
  • Within expiry
  • Properly stored
  • Correctly prepared

Example

An expired reference standard may invalidate assay and impurity results even if chromatography appears acceptable.

Step-by-Step Guide to Performing a GMP-Compliant Remote Review

Step 1: Access the Validated CDS

Examples include:

  • Waters Empower
  • Thermo Chromeleon
  • Agilent OpenLab

Confirm:

  • Authorized access
  • Secure connection
  • Audit trail functionality

Step 2: Review Entire Analytical Sequence

Verify:

  • SST injections
  • Standards
  • Samples
  • Repeats
  • Bracketing standards

Step 3: Evaluate Audit Trails

Review all processing and acquisition audit trails.

Look for:

  • Reprocessing
  • Method changes
  • Deleted results
  • Manual integrations

Step 4: Assess Chromatograms

Confirm:

  • Peak identification
  • Peak integration
  • Baseline assignment
  • Resolution

Step 5: Verify Calculations

Review:

  • Reporting methods
  • Response factors
  • Potency corrections
  • Final results

Step 6: Review Metadata

Verify:

  • User actions
  • Time stamps
  • Electronic signatures
  • Processing history

Step 7: Document Review Completion

Record:

  • Reviewer name
  • Date
  • Findings
  • Approval decision

Practical Example 1: HPLC Assay Review

Scenario

QA remotely reviews assay data generated in Empower.

Findings

  • SST passes
  • Sequence complete
  • No unauthorized integrations
  • Audit trail clean

Outcome

Data approved.

Practical Example 2: Impurity Testing Review

Scenario

LC analysis shows one manually integrated impurity peak.

Reviewer Action

Verify:

  • SOP permits manual integration
  • Justification documented
  • Audit trail reflects change

Outcome

Approved after documented scientific rationale.

Practical Example 3: OOS Investigation

Scenario

A failing assay result is followed by multiple reinjections.

Reviewer Observation

Audit trail reveals selective reprocessing.

Outcome

Formal OOS investigation initiated.

Common Regulatory Inspection Findings

FindingAgency Concern
No audit trail reviewData integrity weakness
PDF-only reviewIncomplete review
Shared user accountsLack of accountability
Missing metadata reviewTraceability gaps
Excessive reinjectionsTesting into compliance
Unjustified integrationsData manipulation risk

GMP Best Practices for Remote Review

Implement Role-Based Access

Restrict permissions according to job responsibilities.

Review Audit Trails Routinely

Do not limit reviews to investigations.

Validate Remote Access Systems

Remote access must be validated and secure.

Establish SOPs

Create dedicated SOPs covering:

  • Remote review expectations
  • Audit trail review
  • Electronic approvals
  • Escalation procedures

Train Reviewers

Personnel should understand:

  • CDS functionality
  • Data integrity principles
  • Regulatory expectations

GMP and Regulatory Insights

Regulators increasingly recognize remote quality oversight; however, remote review does not reduce compliance obligations.

FDA, MHRA, WHO, and PIC/S inspectors continue to emphasize:

  • Data lifecycle management
  • Audit trail reviews
  • Metadata evaluation
  • Electronic record governance
  • Quality culture

Organizations that review chromatographic data directly within validated CDS environments and document every review step are better positioned to withstand regulatory scrutiny.

FAQs

1. What is remote chromatographic data review?

Remote chromatographic data review is the GMP-compliant evaluation of electronic chromatography records, audit trails, metadata, and analytical results from a remote location.

2. Why is audit trail review important?

Audit trails provide visibility into data creation, modification, deletion, and processing activities, supporting data integrity compliance.

3. Can QA review only PDF chromatographic reports?

No. GMP expectations require review of original electronic records within the validated CDS.

4. What are ALCOA+ principles?

ALCOA+ defines data integrity requirements including attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available data.

5. Which CDS platforms are commonly used?

Waters Empower, Thermo Chromeleon, and Agilent OpenLab are widely used in GMP laboratories.

6. What should reviewers check in system suitability tests?

Resolution, tailing factor, theoretical plates, retention time consistency, and %RSD acceptance criteria.

7. Are manual integrations allowed under GMP?

Yes, when scientifically justified, documented, and performed according to approved SOPs.

8. What is metadata in chromatography?

Metadata includes timestamps, user actions, processing history, and system-generated information associated with chromatographic records.

9. What regulations govern remote review?

FDA Data Integrity Guidance, 21 CFR Part 11, EU GMP Annex 11, WHO TRS 1025, and PIC/S guidance.

10. What are common inspection findings related to chromatographic reviews?

Lack of audit trail review, incomplete raw data review, unjustified integrations, and inadequate electronic record controls.